DELAYED UPDATE — PTGX after FDA approval of MIMRYLO; analysts raise buy targets
Protagonist Therapeutics said the FDA approved MIMRYLO (rusfertide) in Aug 2026 for erythrocytosis in adult polycythemia vera. Phase 3 showed sustained hematocrit control; analysts including HC Wainwright, BMO, Barclays and Citi raised price targets while keeping Buy.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) said the FDA approved MIMRYLO (rusfertide) in Aug 2026 for erythrocytosis in adult polycythemia vera after Phase 3 showed sustained hematocrit control, and analysts from HC Wainwright, BMO, Barclays and Citi raised price targets while maintaining Buy vie…